Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations

Vaccine

Volumn 29, Issue 50, 2011, Pages 9385-9390

  Freed, Daniel C ^a   Towne, Victoria M ^a   Casimiro, Danilo R ^a   Zhao, Qinjian ^a,b   Fu, Tong Ming ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b XIAMEN UNIVERSITY   (China)

Author keywords

Adjuvant; Functional Abs; HBsAg; HBV; Inhibition titers; ISCOMATRIX adjuvant; ISS1018; RFHBs1

Indexed keywords

ALUMINUM; AMORPHOUS ALUMINUM HYDROXYLPHOSPHATE SULFATE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; ISCOMATRIX; ISS 1018; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RFHBS1; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BINDING COMPETITION; CONFORMATION; DRUG FORMULATION; EVALUATION; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VIRUS PARTICLE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; CHOLESTEROL; DRUG COMBINATIONS; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; IMMUNOENZYME TECHNIQUES; MACACA MULATTA; MALE; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHOLIPIDS; SAPONINS; VACCINES, SYNTHETIC;

EID: 80855143760     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.122     Document Type: Article

References (28)

1. Garcon N., Chomez P., Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6:723-739.
2. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5:505-517.
3. Harandi A.M., Davies G., Olesen O.F. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines 2009, 8:293-298.
4. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
5. Hadler S.C., Francis D.P., Maynard J.E., Thompson S.E., Judson F.N., Echenberg D.F., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986, 315:209-214.
6. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980, 303:833-841.
7. Zanetti A.R., Van Damme P., Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008, 26:6266-6273.
8. Waters J.A., O'Rourke S.M., Richardson S.C., Papaevangelou G., Thomas H.C. Qualitative analysis of the humoral immune response to the a determinant of HBs antigen after inoculation with plasma-derived or recombinant vaccine. J Med Virol 1987, 21:155-160.
9. Gavilanes F., Gomez-Gutierrez J., Aracil M., Gonzalez-Ros J.M., Ferragut J.A., Guerrero E., et al. Hepatitis B surface antigen. Role of lipids in maintaining the structural and antigenic properties of protein components. Biochem J 1990, 265:857-864.
10. Halperin S.A., Van Nest G., Smith B., Abtahi S., Whiley H., Eiden J.J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003, 21:2461-2467.
11. Pearse M.J., Drane D. ISCOMATRIX adjuvant for antigen delivery. Adv Drug Deliv Rev 2005, 57:465-474.
12. Waters J.A., Brown S.E., Steward M.W., Howard C.R., Thomas H.C. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res 1992, 22:1-12.
13. Waters J., Pignatelli M., Galpin S., Ishihara K., Thomas H.C. Virus-neutralizing antibodies to hepatitis B virus: the nature of an immunogenic epitope on the S gene peptide. J Gen Virol 1986, 67(Pt 11):2467-2473.
14. Iwarson S., Tabor E., Thomas H.C., Goodall A., Waters J., Snoy P., et al. Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee. J Med Virol 1985, 16:89-96.
15. Wampler D.E., Lehman E.D., Boger J., McAleer W.J., Scolnick E.M. Multiple chemical forms of hepatitis B surface antigen produced in yeast. Proc Natl Acad Sci U S A 1985, 82:6830-6834.
16. Zhao Q., Wang Y., Freed D., Fu T.M., Gimenez J.A., Sitrin R.D., et al. Maturation of recombinant hepatitis B virus surface antigen particles. Hum Vaccin 2006, 2:174-180.
17. Barry M., Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin Biol Ther 2007, 7:1731-1737.
18. Waters J.A., Bailey C., Love C., Thomas H.C. A study of the antigenicity and immunogenicity of a new hepatitis B vaccine using a panel of monoclonal antibodies. J Med Virol 1998, 54:1-6.
19. High K., Meng Y., Washabaugh M., Zhao Q. Determination of picomolar equilibrium dissociation constants in solution by enzyme-linked immunosorbent assay with fluorescence detection. Anal Biochem 2005, 347:159-161.
20. Meng Y., High K., Antonello J., Washabaugh M., Zhao Q. Enhanced sensitivity and precision in an enzyme-linked immunosorbent assay with fluorogenic substrates compared with commonly used chromogenic substrates. Anal Biochem 2005, 345:227-236.
21. Boland G., Beran J., Lievens M., Sasadeusz J., Dentico P., Nothdurft H., et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004, 23:316-320.
22. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004, 24:693-701.
23. Cambron P., Jacquet J.M., Hoet B., Lievens M. Development and technical and clinical validation of a quantitative enzyme-linked immunosorbent assay for the detection of human antibodies to hepatitis B surface antigen in recipients of recombinant hepatitis B virus vaccine. Clin Vaccine Immunol 2009, 16:1236-1246.
24. Abou-Jaoude G., Sureau C. Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J Virol 2007, 81:13057-13066.
25. Salisse J., Sureau C. A function essential to viral entry underlies the hepatitis B virus a determinant. J Virol 2009, 83:9321-9328.
26. Zuckerman J.N., Zuckerman A.J. Mutations of the surface protein of hepatitis B virus. Antiviral Res 2003, 60:75-78.
27. Mangold C.M., Streeck R.E. Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein. J Virol 1993, 67:4588-4597.
28. Le Duff Y., Blanchet M., Sureau C. The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent. J Virol 2009, 83:12443-12451.